Corvus Pharmaceuticals Stock Performance
| CRVS Stock | USD 8.94 0.70 8.50% |
Corvus Pharmaceuticals holds a performance score of 21 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of -0.54, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Corvus Pharmaceuticals are expected to decrease at a much lower rate. During the bear market, Corvus Pharmaceuticals is likely to outperform the market. Use Corvus Pharmaceuticals value at risk, as well as the relationship between the kurtosis and market facilitation index , to analyze future returns on Corvus Pharmaceuticals.
Risk-Adjusted Performance
21 of 100
Weak | Strong |
Solid
Compared to the overall equity markets, risk-adjusted returns on investments in Corvus Pharmaceuticals are ranked lower than 21 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively unfluctuating basic indicators, Corvus Pharmaceuticals unveiled solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 13.2 M |
Corvus |
Corvus Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 413.00 in Corvus Pharmaceuticals on August 24, 2024 and sell it today you would earn a total of 481.00 from holding Corvus Pharmaceuticals or generate 116.46% return on investment over 90 days. Corvus Pharmaceuticals is currently generating 1.3305% in daily expected returns and assumes 4.9238% risk (volatility on return distribution) over the 90 days horizon. In different words, 43% of stocks are less volatile than Corvus, and 74% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Corvus Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Corvus Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Corvus Pharmaceuticals, and traders can use it to determine the average amount a Corvus Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.2702
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | CRVS | |||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 4.92 actual daily | 43 57% of assets are more volatile |
Expected Return
| 1.33 actual daily | 26 74% of assets have higher returns |
Risk-Adjusted Return
| 0.27 actual daily | 21 79% of assets perform better |
Based on monthly moving average Corvus Pharmaceuticals is performing at about 21% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Corvus Pharmaceuticals by adding it to a well-diversified portfolio.
Corvus Pharmaceuticals Fundamentals Growth
Corvus Stock prices reflect investors' perceptions of the future prospects and financial health of Corvus Pharmaceuticals, and Corvus Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Corvus Stock performance.
| Return On Equity | -0.45 | ||||
| Return On Asset | -0.24 | ||||
| Current Valuation | 488.18 M | ||||
| Shares Outstanding | 64.26 M | ||||
| Price To Earning | (5.64) X | ||||
| Price To Book | 42.67 X | ||||
| EBITDA | (26.88 M) | ||||
| Cash And Equivalents | 56.72 M | ||||
| Cash Per Share | 1.22 X | ||||
| Total Debt | 1.37 M | ||||
| Debt To Equity | 0.04 % | ||||
| Book Value Per Share | 0.79 X | ||||
| Cash Flow From Operations | (23.93 M) | ||||
| Earnings Per Share | (0.99) X | ||||
| Total Asset | 45.55 M | ||||
| Retained Earnings | (334.72 M) | ||||
| Current Asset | 78.53 M | ||||
| Current Liabilities | 6.42 M | ||||
About Corvus Pharmaceuticals Performance
Assessing Corvus Pharmaceuticals' fundamental ratios provides investors with valuable insights into Corvus Pharmaceuticals' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Corvus Pharmaceuticals is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. The company was incorporated in 2014 and is based in Burlingame, California. Corvus Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 28 people.Things to note about Corvus Pharmaceuticals performance evaluation
Checking the ongoing alerts about Corvus Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Corvus Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Corvus Pharmaceuticals appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (27.03 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Corvus Pharmaceuticals currently holds about 56.72 M in cash with (23.93 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.22. |
- Analyzing Corvus Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Corvus Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Corvus Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Corvus Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Corvus Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Corvus Pharmaceuticals' stock. These opinions can provide insight into Corvus Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Corvus Stock Analysis
When running Corvus Pharmaceuticals' price analysis, check to measure Corvus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Corvus Pharmaceuticals is operating at the current time. Most of Corvus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Corvus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Corvus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Corvus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.